Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Down 33.4% in July

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a significant drop in short interest during the month of July. As of July 15th, there was short interest totaling 8,407 shares, a drop of 33.4% from the June 30th total of 12,617 shares. Based on an average daily volume of 2,362 shares, the days-to-cover ratio is presently 3.6 days. Approximately 4.2% of the shares of the company are short sold.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC lifted its holdings in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the quarter. Jane Street Group LLC owned approximately 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 as of its most recent SEC filing.

Amplify Weight Loss Drug & Treatment ETF Price Performance

Shares of Amplify Weight Loss Drug & Treatment ETF stock opened at $25.86 on Friday. The stock has a market cap of $5.17 million, a PE ratio of 24.31 and a beta of 0.37. The firm has a fifty day moving average price of $25.16 and a 200 day moving average price of $25.16. Amplify Weight Loss Drug & Treatment ETF has a 1 year low of $21.70 and a 1 year high of $27.28.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.